



## **Agilis Biotherapeutics Appoints Dr. Arthur Tzianabos to the Scientific Advisory Board**

**New York, NY, June 5, 2014**—Agilis Biotherapeutics, LLC, a synthetic biology-based company focused on developing best-in-class DNA-based therapeutics for rare genetic diseases, announced today that Arthur Tzianabos, Ph.D., has joined its Scientific Advisory Board. Dr. Tzianabos brings more than 20 years of experience in drug discovery and development of therapeutics in industry and academia. Dr. Tzianabos is currently Chief Scientific Officer of OvaScience, Inc., a global life sciences company developing new fertility treatments. Prior to his leadership role at OvaScience, Dr. Tzianabos was Senior Vice President of Research and Non-Clinical Development at Shire Human Genetic Therapies.

“We are thrilled to welcome Dr. Tzianabos to our Scientific Advisory Board,” said G. Houston Hall, Chairman of Agilis. “Arthur shares our commitment to patients that are suffering from Friedreich’s ataxia. He also brings a wealth of experience in developing treatments for rare diseases that will assist us in the development and commercialization of Agilis therapies for this life-threatening disease.”

Dr. Tzianabos joined Shire in 2005 as Senior Director, Discovery Research and was instrumental in establishing the Discovery Research group and played a leading role in the expansion of Shire HGT research pipeline shortly after the acquisition of TKT by Shire. In 2008, Arthur became the VP of Program Management and was responsible for the management of the cross-functional Program teams that oversaw Development programs from the pre-clinical phase through commercialization. Prior to joining Shire, Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. He was a faculty member since 1992. In addition, Dr. Tzianabos served as a consultant to several biotechnology companies, including Genzyme Corporation and Eli Lilly. He has published more than 80 scientific papers, reviews, book chapters and patents. Dr. Tzianabos holds a B.S. in Biology and a Ph.D. in Microbiology.

“I am happy to be part of Agilis at this exciting stage of the company’s development,” said Dr. Tzianabos. “I look forward to helping Agilis develop novel therapies for rare genetic diseases, such as Friedreich’s ataxia.”

**About Agilis Biotherapeutics, LLC**

Agilis Biotherapeutics, LLC, is a biotechnology company focused on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are limited or no treatment options. We believe that engineered DNA-based therapeutics provide the ability to target underlying disease mechanisms with tightly-controlled multigenic modalities leading to “functional cures” for patients with these diseases.

We invite you to visit our website at [www.agilisbio.com](http://www.agilisbio.com)

**Safe Harbor Statement**

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

**For more information contact:**

**Agilis Biotherapeutics**

Dr. Jodi Cook

Vice President, Operations

Email: [jcook@agilisbio.com](mailto:jcook@agilisbio.com)

Phone: 510-673-7809